Objective: To investigate the factors influencing venlafaxine blood concentration exceeding the alert threshold in patients with depression and to develop a risk prediction model for elevated venlafaxine concentrations, providing a reference for individualized VEN therapy.
Methods: A retrospective analysis was conducted on 590 hospitalized patients who received venlafaxine treatment and underwent TDM at the First Hospital of Hebei Medical University between January 2021 and August 2024. Patients were categorized into a target concentration group (100-400 ng/mL) and an above-alert group (> 800 ng/mL) based on their VEN plasma concentrations. Demographic and clinical variables, including sex, age, body mass index (BMI), average daily dose, plasma albumin level, concomitant medications, liver and kidney function, were collected and compared between groups. Logistic regression analysis was performed to identify independent risk factors associated with VEN concentrations exceeding the alert threshold. A nomogram prediction model was constructed based on the identified factors and was subsequently validated.
Results: Among the 590 patients, 516 were in the target concentration group and 74 were in the above-alert group. The proportion of females, patients with BMI < 24, average daily dose ≥ 225 mg, renal impairment, and concomitant use of CYP2D6 inhibitors was significantly higher in the above-alert group than in the target group (P < 0.05). Logistic regression analysis revealed that average daily dose ≥ 225 mg (OR = 26.628, 95 % CI: 12.912-54.916), renal impairment (OR = 2.429, 95 % CI: 1.215-4.854), and concomitant use of CYP2D6 inhibitors (OR = 5.232, 95 % CI: 2.781-9.844) were independent risk factors for VEN concentrations exceeding the alert threshold (P < 0.05). The nomogram model showed an AUC of 0.899 (95 % CI: 0.864-0.935), sensitivity of 48.65 %, specificity of 95.74 %, positive predictive value of 62.07 %, and negative predictive value of 92.86 %. Bootstrap validation demonstrated good consistency (Brier score = 0.072), and the Hosmer-Lemeshow test indicated good calibration (χ2 = 3.16, P = 0.531). Decision curve analysis demonstrated clinical utility for threshold probabilities of 0.05-0.80.
Conclusions: Average daily dose ≥ 225 mg, renal impairment, and concomitant use of CYP2D6 inhibitors are independent risk factors for VEN plasma concentrations exceeding the alert threshold. The constructed nomogram model effectively predicts the risk of venlafaxine concentration exceeding the alert range and has significant clinical application value.
Declarations
Not applicable.
Authors' contributions
Y. Zhang: conception and design of the study, feasibility assessment, and drafting and revising the manuscript. J. Yu: quality control, critical revision, and overall supervision of the study. Y. Zhang, X. Li, Y. Liu, J. Wang: data collection, organization and analysis. Y. Zhang, C. Zhou, J. Yu: interpretation and analysis of the results.
Ethics approval and consent to participate
This study was approved by the Clinical Research Ethics Committee of the First Hospital of Hebei Medical University (No. 20220936).
Consent for publication
Not applicable.
Availability of data and materials
Not applicable.
Funding
This study was supported by the Project of Hebei Provincial Department of Finance (ZF2023020) and the Medical Research Project of Hebei Provincial Health Commission (20221440).
Declarations of Competing interests
The authors declare that they have no competing interests.
Acknowledgements
Not applicable.
Authors' other information
Not applicable.
| [1] |
Wang Xin, Wu Guodong, An Ming, et al. Research progress on the PK-PD relationship and influencing factors of venlafaxine. Chin J Clin Pharmacol Ther. 2023; 28(07):788-795.
|
| [2] |
Couderc S, Mory C, Darnaud L, et al. Therapeutic drug monitoring of antidepressants: why venlafaxine is the most monitored drug? A review of literature. Therapie. 2021; 76(6):725-733. https://doi.org/10.1016/j.therap.2021.01.052
|
| [3] |
Wang ZZ, Deng SH, Lu HY, et al. Effect of venlafaxine dosage, valproic acid concentration, sex, and age on steady state dose-corrected concentrations of venlafaxine and O-desmethylvenlafaxine: a retrospective analysis of therapeutic drug monitoring data in a Chinese population. Hum Psychopharmacol. 2020; 35(3):e2733. https://doi.org/10.1002/hup.2733
|
| [4] |
Lense XM, Hiemke C, Funk C, et al. Venlafaxine's therapeutic reference range in the treatment of depression revised: a systematic review and meta-analysis. Psychopharmacology. 2024; 241(2):275-289. https://doi.org/10.1007/s00213-023-06484-7
|
| [5] |
Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: 2017 edition. Pract Pharm Clin Remedies. 2022; 25(02):97-118. https://doi.org/10.14053/j.cnki.ppcr.202202001
|
| [6] |
Liang Hai, Xia Runan, Wu Wei, et al. Advances in research on factors influencing venlafaxine plasma concentration. Chin J Hosp Pharm. 2023; 43(15):1758-1762. https://doi.org/10.13286/j.1001-5213.2023.15.19
|
| [7] |
Xie Huanshan, Chen Hongzhen, Wang Zhanzhang, et al. Pharmacokinetics and safety evaluation of venlafaxine based on cytochrome P 450 gene polymorphism. Chin J Clin Pharmacol. 2019; 35(19):2426-2429+ 2438. https://doi.org/10.13699/j.cnki.1001-6821.2019.19.061
|
| [8] |
Zeng Li, Zhao Yin, Shuzhang Du. Establishment and validation of a risk prediction model for subtherapeutic blood tacrolimus concentrations. Chin Pharm J. 2024; 59(10):945-950.
|
| [9] |
Sigurdsson HP, Hefner G, Ben-Omar N, et al. Steady-state serum concentrations of venlafaxine in patients with late-life depression. Impact of age, sex and BMI. J Neural Transm. 2015; 122(5):721-729. https://doi.org/10.1007/s00702-014-1317-9
|
| [10] |
Paulzen M, Haen E, Hiemke C, et al. Antidepressant polypharmacy and the potential of pharmacokinetic interactions: doxepin but not mirtazapine causes clinically relevant changes in venlafaxine metabolism. J Affect Disord. 2018; 227:506-511. https://doi.org/10.1016/j.jad.2017.11.046
|
| [11] |
Zhang Yanjing, Yu Jing, Wang Jing, et al. Analysis of laboratory alert concentrations of olanzapine in therapeutic drug monitoring. China Pharm. 2023; 32(15):113-117.
|
| [12] |
Li Jing, Duan Zihao, Shen Bingxiang, et al. Establishment and evaluation of a risk prediction model for digoxin blood concentration exceeding safe limits. Chin J Hosp Pharm. 2021; 41(13):1332-1336. https://doi.org/10.13286/j.1001-5213.2021.13.11
|
| [13] |
Zhou Juxiang, Li Yanfei, Lü Fangjun, et al. Construction of a risk prediction model for elevated voriconazole plasma concentrations. Chin J Clin Pharmacol Ther. 2024; 29(06):653-660.
|
| [14] |
Depression. Evidence Update April 2012: A Summary of Selected New Evidence Relevant to NICE Clinical Guideline 90 ‘The Treatment and Management of Depression in Adults’ [Internet]. London: National Institute for Health and Clinical Excellence (NICE); 2009-2012.
|
| [15] |
American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry. 2000; 157(4_):1-45.
|
| [16] |
Furukawa TA, Cipriani A, Cowen PJ, et al. Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. Lancet Psychiatry. 2019; 6(7):601-609. https://doi.org/10.1016/S2215-0366(19)30217-2
|
| [17] |
Wang ZZ, Deng SH, Lu HY, et al. Effect of venlafaxine dosage, valproic acid concentration, sex, and age on steady state dose-corrected concentrations of venlafaxine and O-desmethylvenlafaxine: a retrospective analysis of therapeutic drug monitoring data in a Chinese population. Hum Psychopharmacol. 2020; 35(3):e2733. https://doi.org/10.1002/hup.2733
|
| [18] |
Troy SM, Schultz RW, Parker VD, et al. The effect of renal disease on the disposition of venlafaxine. Clin Pharm Ther. 1994; 56(1):14-21. https://doi.org/10.1038/clpt.1994.95
|
| [19] |
Xie Huanshan, Huang Yi, Huang Shanqing, et al. Analysis of influencing factors for the concentration ratio of O-desmethylvenlafaxine to venlafaxine based on therapeutic drug monitoring. Chin J Clin Pharmacol. 2022; 38(20):2419-2422. https://doi.org/10.13699/j.cnki.1001-6821.2022.20.008
|
| [20] |
Cho CK, Kang P, Jang CG, et al. PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug-drug interactions with clarithromycin and paroxetine. Arch Pharm Res. 2024; 47(5):481-504. https://doi.org/10.1007/s12272-024-01495-0
|
| [21] |
Weilong Jing, yu Chen, jiting Geng, et al. Study on the correlation between CYP2D6 gene polymorphism and venlafaxine metabolism in patients with depression. Chin J Hosp Pharm. 2019; 39(05):497-501. https://doi.org/10.13286/j.cnki.chinhosppharmacyj.2019.05.14
|
PDF
(1254KB)
